Sandoz Grabs FDA Approval for Generic of Teva's Copaxone

Apr 16, 2015

Philadelphia Business Journal

The FDA has approved the first generic version of Teva's top branded product, multiple sclerosis drug Copaxone.

Sandoz, a German generics company owned by Novartis, received FDA approval to market a generic injectable drug containing Copaxone’s active ingredient, glatiramer acetate. The Sandoz version will be knows as Glatopa.

Teva's litigation has been extensive since a U.S. appeals court threw out the Copaxone patent in 2013, and court battles on patent issues still ongoing.

Read the Philadelphia Biz Journal article